Clinical Trial of Efficacy of Dashmoola Haritaki Avaleha in Tamaka Shwasa with special reference to Bronchial Asthma
Phase 3
- Conditions
- Health Condition 1: J454- Moderate persistent asthma
- Registration Number
- CTRI/2024/04/065734
- Lead Sponsor
- Dr Salma Momin
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Patients with Classical signs and symptoms of Tamaka Shwasa with special reference to bronchial asthma
2.Age group 20-70yrs
3.Either Gender
4.Mild and moderate grade of Bronchial Asthma as per GINA
5.Patient indicated for Koshta Shodhana
6.Patient willing to participate with Written Consent.
Exclusion Criteria
1.The patients diagnosed with COPD ( Chronic bronchitis, Emphysema), Pneumonia, Cardiac asthma, Tuberculosis, Pleural effusion, Cardiac pathology.
2.Patients with Status Asthamaticus
3.Patients with Diabetes Mellitus and Hypertension, Uraemia, Acidosis, Malignancy .
4.Pregnant Woman, Lactating Woman
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method •To evaluate the efficacy of Dashmoola Haritaki Avaleha in Tamaka Shwasa with special reference to Bronchial Asthma. <br/ ><br>•To compare the effect of Dashmoola Haritaki Avaleha and Vasa Avaleha in Tamaka Shwasa with special reference to Bronchial Asthma. <br/ ><br>•To compare the effect of Dashmoola Haritaki Avaleha and Vasa Avaleha in Health related Quality of Life According to GINA Guidelines. <br/ ><br>Timepoint: Subjective parameters will be assessed on <br/ ><br>baseline on 0th day ,2nd week and 4th week and 45th day of <br/ ><br>the intervention. <br/ ><br>
- Secondary Outcome Measures
Name Time Method CBC ESR AEC and SPIROMETERY test will be done on 0th day and 45th day of the intervention.Timepoint: Objective parameters will be assessed on <br/ ><br>baseline on 0th day ,2nd week and 4th week and 45th day of <br/ ><br>the intervention.